Summary
- PMV Pharmaceuticals has filed proposed terms for its U.S. IPO plan.
- The firm is developing treatments for various cancers.
- PMVP just received approval to enter Phase 1 trials for its lead candidate.
- The company is still an ultra-early stage, so the IPO may be more suited to institutional investors.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
PMV Pharmaceuticals (PMVP) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing tumor agnostic gene therapies for a wide range of cancers.
While PMVP has recently received approval to enter Phase 1 trials for its lead candidate, the firm is still at a preclinical stage of development and thus is likely more suited to long-term hold institutional investors.
Company & Technology
Cranbury, New Jersey-based PMV was founded to develop treatment technologies seeking to correct p53 mutations in proteins, thereby reinstating their tumor-suppressing function.
Management is headed by president and Chief Executive Officer Mr. David Mack, Ph.D., who has been with the firm since June 2013 and was previously a general partner at venture capital firm Alta Partners and before that VP of Genomics Research at Eos Biotechnology.
Below is a brief overview video of the p53 protein mutation:
